ADMA BIOLOGICS, INC.
About ADMA BIOLOGICS, INC.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $510.2M
- Net income
- $146.9M
- Total assets
- $624.2M
- Market cap
- $1.8B
- Gross margin
- 57.4%
- Operating margin
- 37.5%
- Net margin
- 28.8%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $510.2M
- Cost of revenue
- $217.4M
- Gross profit
- $292.8M
- Operating expenses
- $101.3M
- Operating income
- $191.4M
- Income tax
- $35.7M
- Net income
- $146.9M
- EPS (basic)
- $0.62
- EPS (diluted)
- $0.60
Balance sheet
- Total assets
- $624.2M
- Current assets
- $466.5M
- Total liabilities
- $146.9M
- Current liabilities
- $69.5M
- Shareholders’ equity
- $477.3M
Cash flow
- Operating cash flow
- $50.4M
- Investing cash flow
- -$21.9M
- Financing cash flow
- -$44.0M
- Net cash flow
- -$15.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.8B
- P/E ratio
- 13.4
- EPS (diluted)
- $0.6
- Shares outstanding
- 229.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 17, 2013
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $146.9M in FY2025.
- Revenue grew 530% from FY2021 to FY2025.
- Gross margin of 57.4%, net margin 28.8%.
- Trading 66% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 13.4.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review ADMA BIOLOGICS, INC..
Write a review
News about ADMA BIOLOGICS, INC.
News & sentiment via Polygon.io
